Make an Inquiry
Accelerating Kidney Transplant Rejection Drug Development

Transplant rejection remains a critical barrier to long-term kidney graft survival, demanding innovative therapeutic solutions to improve patient outcomes. Protheragen is a specialized partner in preclinical drug development for transplant rejection and kidney therapeutics, offering an integrated approach to advance novel candidates from target validation through IND-enabling studies. Leveraging deep scientific expertise and state-of-the-art platforms, Protheragen delivers robust in vitro and in vivo models, biomarker discovery, PK/PD analysis, and comprehensive safety pharmacology tailored to the complexities of transplant immunology and renal pathophysiology. Our operations are grounded in rigorous regulatory compliance, ensuring that each stage of development aligns with global standards and expedites the path to clinical evaluation. Protheragen’s commitment is to accelerate the discovery and development of transformative therapies for kidney transplant rejection, empowering our partners to address unmet medical needs and improve patient lives.

What is Kidney Transplant RejectionTargets for Kidney Transplant RejectionDrug Discovery and Development ServicesWhy Choose Us

What is Kidney Transplant Rejection

Kidney transplant rejection is a major immunological complication following renal transplantation, resulting from the recipient’s immune system identifying the transplanted kidney as foreign. The etiology involves both cellular and humoral immune mechanisms, with T lymphocytes and antibodies targeting donor antigens, particularly human leukocyte antigens (HLA). This immune response can manifest as hyperacute, acute cellular, antibody-mediated, or chronic rejection, each with distinct pathophysiological pathways. Hyperacute rejection is mediated by preformed antibodies and is now rare, while acute cellular rejection is driven by T-cell infiltration early after transplantation. Antibody-mediated rejection involves donor-specific antibodies causing vascular injury, and chronic rejection is characterized by ongoing immune injury and non-immunological factors, leading to gradual graft dysfunction. Clinically, kidney transplant rejection presents with signs of graft dysfunction such as rising serum creatinine, decreased urine output, hypertension, and proteinuria. Diagnosis is multifaceted, combining clinical assessment, laboratory evaluation for renal function and donor-specific antibodies, imaging, and definitive renal allograft biopsy, which is interpreted using the Banff classification. Treatment strategies focus on immunosuppression, utilizing drugs such as tacrolimus, mycophenolate mofetil, belatacept, everolimus, sirolimus, basiliximab, rituximab, and newer agents like imlifidase. Early detection and prompt therapy are essential to reverse acute rejection, preserve graft function, and improve long-term transplant outcomes.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
imlifidase (USAN) 1947415-68-0
belatacept (Prop INN; USAN) 706808-37-9
img-159351-69-6-everolimus-rec-inn-usan everolimus (Rec INN; USAN) 159351-69-6 C53 H83 N O14 958.224
img-24280-93-1-free-acid37415-62-6-mycophenolate-sodium-usanmycophenolic-acid-sodium- mycophenolate sodium (USAN); mycophenolic acid sodium salt (Rec INNM; BANM) 24280-93-1 (free acid); 37415-62-6 C17 H19 O6 . Na 342.319
img-53123-88-9---rapamycinrapamycinsirolimus-rec-inn-usan-ban (-)-rapamycin; rapamycin; sirolimus (Rec INN; USAN; BAN) 53123-88-9 C51 H79 N O13 914.172
basiliximab (Prop INN; USAN) 179045-86-4
rituximab (Prop INN; USAN) 174722-31-7
img-128794-94-5-mycophenolate-mofetil-usan-ban mycophenolate mofetil (USAN; BAN) 128794-94-5 C23 H31 N O7 433.495
img-85468-01-5-15-deoxyspergualindeoxyspergualin-hydrochloridegus 15-deoxyspergualin; deoxyspergualin hydrochloride; gusperimus hydrochloride (Rec INNM; JAN); gusperimus trihydrochloride (USAN) 85468-01-5 C17 H37 N7 O3 . 3 Cl H 496.904
img-104987-11-3-fujimycintacrolimus-rec-inn-usan-ban fujimycin; tacrolimus (Rec INN; USAN; BAN) 104987-11-3 C44 H69 N O12 804.018

Learn More

Targets for Kidney Transplant Rejection

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
ATP binding cassette subfamily B member 1 ABCB1
C-C motif chemokine receptor 5 CCR5
CD19 molecule CD19
CD3 Complex (T Cell Receptor Complex)
hydroxycarboxylic acid receptor 2 HCAR2
FKBP prolyl isomerase 1A FKBP1A
CD86 molecule CD86
CD80 molecule CD80
Proteasome Complex
protein phosphatase 3 catalytic subunit beta PPP3CB

Kidney transplant rejection is driven by a network of immune pathways, with key molecular targets mediating the recognition and attack of the allograft. Central to this process are T cell co-stimulatory molecules such as CD80 and CD86, which interact with receptors on T cells to promote their activation and proliferation. The interleukin-2 receptor alpha (IL2RA) is critical for T cell clonal expansion, while intracellular signaling proteins like MTOR and FKBP1A regulate T cell growth and response via the mTOR and calcineurin pathways. Calcineurin subunits (PPP3CB, PPP3CC, PPP3R1) are essential for activating NFAT-dependent transcription and cytokine production. In addition, CCR5 mediates immune cell trafficking to the graft, and B cell markers such as CD19 and MS4A1 (CD20) are involved in antibody-mediated rejection. The glucocorticoid receptor NR3C1 modulates immune responses through corticosteroid signaling. Therapeutically, these targets have shaped the development of modern immunosuppressive regimens. Agents like belatacept block CD80/CD86, while basiliximab targets IL2RA, and mTOR inhibitors (sirolimus, everolimus) act on MTOR-FKBP1A complexes. Calcineurin inhibitors (tacrolimus, cyclosporine) suppress PPP3CB/PPP3CC activity. Anti-CD20 monoclonal antibodies (rituximab) and investigational anti-CD19 therapies address antibody-mediated rejection. CCR5 antagonists (maraviroc) and corticosteroids targeting NR3C1 further expand the therapeutic arsenal. These advances have improved graft outcomes, enabled tailored immunosuppression, and fostered ongoing research into more targeted, less toxic interventions for kidney transplant recipients.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates the discovery and optimization of therapies for kidney transplant rejection. We offer robust chemiluminescent, fluorescent, flow cytometry, and FACS-based assays to evaluate immune cell activation, cytokine production, and cytotoxicity. Key targets include CD80, CD86, FKBP1A, mTOR kinase, and MS4A1. We quantitatively assess drug potency (IC-50) and binding affinity (Kd), providing comprehensive data to inform therapeutic development. Our advanced platforms deliver precise, reproducible results, enabling clients to screen, characterize, and prioritize candidate compounds targeting immune-mediated mechanisms underlying kidney transplant rejection with confidence and scientific rigor.

Cd80 Molecule Cd86 Molecule
Fkbp Prolyl Isomerase 1A Mechanistic Target Of Rapamycin Kinase
Membrane Spanning 4-Domains A1

Learn More

Why Choose Us

Choosing Protheragen as your partner in the development of new therapeutics for transplant rejection and kidney-related conditions means entrusting your project to a team with deep, specialized expertise in this complex field. At Protheragen, our professional teams are comprised of industry-leading scientists and clinicians dedicated to advancing kidney and transplant rejection research. We leverage advanced technology platforms and innovative methodologies to accelerate drug discovery and preclinical development, ensuring that every project benefits from the latest scientific advancements. Our proven track record in preclinical drug development services reflects our reliability and commitment to delivering results that meet the highest quality standards. Protheragen adheres strictly to regulatory compliance at every stage, ensuring that all processes align with global standards and best practices. Above all, we are committed to making a meaningful impact in the fight against transplant rejection and kidney disease, working tirelessly to bring new, effective therapeutics to patients in need. Trust Protheragen to provide the professionalism, reliability, and scientific excellence your project deserves.

FAQs for Our Services

Q: What are the main preclinical research challenges unique to developing drugs for kidney transplant rejection?

A: Developing drugs for kidney transplant rejection presents specific preclinical challenges, including the need for highly predictive animal models that accurately mimic human immune responses and rejection mechanisms. There are also complexities in evaluating immunosuppression efficacy versus toxicity, as well as the need to assess drug effects on both graft survival and renal function. Our company addresses these challenges by employing advanced in vivo and ex vivo models, incorporating humanized immune system models where possible, and utilizing robust biomarker analysis to monitor both efficacy and safety.

Q: What regulatory considerations are important in the preclinical development of drugs for kidney transplant rejection?

A: Regulatory agencies such as the FDA and EMA require comprehensive safety and efficacy data from preclinical studies before approving clinical trials for anti-rejection therapies. This includes immunotoxicology assessments, pharmacokinetic/pharmacodynamic profiling, and demonstration of efficacy in relevant animal models. Our team has extensive experience designing preclinical programs that align with regulatory guidelines, ensuring that all necessary endpoints—including graft survival, immune modulation, and off-target effects—are thoroughly evaluated and documented for regulatory submission.

Q: What technical aspects should be considered in preclinical research for transplant rejection, kidney?

A: Technical considerations include the selection of appropriate animal models (e.g., rodent or non-human primate models of kidney transplantation), the use of relevant immunological assays, and the implementation of advanced imaging and histopathological techniques to assess graft integrity and immune infiltration. Our company utilizes state-of-the-art technologies for immune profiling, cytokine measurement, and longitudinal monitoring of graft function, ensuring high-quality and reproducible data throughout the preclinical phase.

Q: What are the typical timeline and cost considerations for preclinical drug development targeting kidney transplant rejection?

A: Preclinical development for kidney transplant rejection drugs typically spans 18-36 months, depending on the complexity of the program and regulatory requirements. Costs can vary significantly, but generally range from $2 million to $6 million, covering in vitro studies, multiple animal models, toxicology, and regulatory documentation. Our team works closely with clients to optimize study design, streamline timelines, and provide transparent budgeting to ensure efficient resource allocation and cost control.

Q: What are the key success factors in preclinical drug development for kidney transplant rejection?

A: Success in preclinical development hinges on selecting predictive models, establishing robust efficacy and safety endpoints, and generating high-quality, reproducible data to support regulatory filings. Early identification of potential safety liabilities, effective project management, and clear communication with regulatory authorities are also critical. Our company’s integrated approach—combining scientific expertise, regulatory know-how, and advanced technologies—maximizes the likelihood of successful translation from preclinical research to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.